loader image

Pα+ Psychedelic Patent Analysis: April 2024

Reading Time: < 1 minute


General Overview
A CaaMTech & ASRI Collaboration
GH Research & Beckley Psytech: An Update
CaaMTech Grows Tryptamine Patent Portfolio
Atai Sees Two New Allowances to Support DMT Program

***

Each month, we provide an interactive database of psychedelic patents that were granted, allowed, abandoned, rejected or that had responses filed.

We then provide detail and analysis on a handful of specific cases, or one deep dive.
Our monthly Psychedelic Patent Analysis is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

Companies, organisations and candidates mentioned in this analysis: DemeRx, Axsome Therapeutics, Empyrean Neuroscience, Tactogen, Clexio Biosciences, CLE-100, Gilgamesh Pharmaceuticals, MindMed, Awakn Life Sciences, and others.



Source link

share this article
  • This field is for validation purposes and should be left unchanged.

Subscribe to receive the latest business and industry news in your inbox.

  • This field is for validation purposes and should be left unchanged.

latest from the industry
PSYCHEDELICS news

Whitepaper

  • This field is for validation purposes and should be left unchanged.

  • This field is for validation purposes and should be left unchanged.

Use